Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	[1]
Biosecurity revenue:
Total Revenue		$ 80,568	$ 144,618	$ 161,270	$ 313,023
Costs and operating expenses:
Research and development		144,282	290,059	306,921	613,635
General and administrative		102,341	438,427	213,774	873,195
Total operating expenses		264,719	792,397	561,166	1,636,173
Loss from operations		(184,151)	(647,779)	(399,896)	(1,323,150)
Other income (expense):
Interest income, net		14,349	2,264	28,894	2,441
Loss on equity method investments		(67)	(10,166)	(1,516)	(31,053)
Loss on investments		(2,121)	(38,673)	(8,491)	(38,223)
Change in fair value of warrant liabilities		(4,482)	23,509	(3,278)	108,544
Gain on deconsolidation of subsidiary		0	0	0	15,900
Other income, net		3,224	230	6,152	2,149
Total other income (expense), net		10,903	(22,836)	21,761	59,758
Loss before income taxes		(173,248)	(670,615)	(378,135)	(1,263,392)
Income tax expense (benefit)		67	(45)	149	(229)
Net loss		(173,315)	(670,570)	(378,284)	(1,263,163)
Loss attributable to non-controlling interest		0	(1,745)	0	(3,833)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders		$ (173,315)	$ (668,825)	$ (378,284)	$ (1,259,330)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders:
Basic		$ (0.09)	$ (0.41)	$ (0.2)	$ (0.78)
Diluted		$ (0.09)	$ (0.41)	$ (0.2)	$ (0.78)
Weighted average common shares outstanding
Basic		1,933,437	1,620,704	1,924,251	1,614,138
Diluted		1,933,437	1,620,704	1,924,251	1,614,138
Comprehensive loss:
Net loss		$ (173,315)	$ (670,570)	$ (378,284)	$ (1,263,163)
Other comprehensive income (loss):
Foreign currency translation adjustment		314	(3,141)	1,332	(3,781)
Total other comprehensive income (loss)		314	(3,141)	1,332	(3,781)
Comprehensive loss		(173,001)	(673,711)	(376,952)	(1,266,944)
Product [Member]
Biosecurity revenue:
Total Revenue		10,788	3,887	22,454	17,834
Costs and operating expenses:
Cost of Biosecurity revenue		2,034	2,444	6,575	10,539
Service [Member]
Biosecurity revenue:
Total Revenue		24,497	96,489	59,437	229,459
Costs and operating expenses:
Cost of Biosecurity revenue		16,062	61,467	33,896	138,804
Cell Engineering revenue [Member]
Biosecurity revenue:
Total Revenue	[2]	$ 45,283	$ 44,242	$ 79,379	$ 65,730

[1] As adjusted to reflect the impact of the adoption of Accounting Standards Codification Topic 842, Leases (“ASC 842”) as of January 1, 2022. See Note 1 for a summary of the adjustments.

[2] Includes related party revenue of $6,507 and $7,973 for the three months ended June 30, 2023 and 2022, respectively, and $11,212 and $21,501 for the six months ended June 30, 2023 and 2022, respectively.